Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMass General Brigham Dry Eye Prior Auth | OpenPaye…
    Ask Trek AI about this page
    CurrentMass General Brigham Health PlanPolicy N/A

    Dry Eye Disease: Miebo, Restasis, Restasis Multidose, Tryptyr, and Xiidra

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization coverage under the commercial/Exchange pharmacy benefit for Miebo, Restasis, Restasis Multidose, Tryptyr, and Xiidra for members with dry eye disease. It establishes initial authorization, continuation, documentation, and authorization-duration requirements.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyDry Eye Disease: Miebo, Restasis, Restasis Multidose, Tryptyr, and Xiidra
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateJan 1, 202743d
    Last ReviewSep 9, 2026
    Next Review DateNot specified
    Key ActionSubmit prior authorization with documentation of dry eye disease and trial and failure of, or intolerance to, artificial tears.
    SourceLink
    POLICY UPDATE CHANGES

    The policy adds Miebo and Tryptyr coverage criteria for dry eye disease.

    The policy adds Xiidra criteria to the dry eye disease policy.

    Restasis and Restasis Multidose coverage criteria require consideration of concurrent ophthalmic anti-inflammatory therapy.

    4Covered drug products or product families
    12 monthsInitial approval and reauthorization duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    90 days
    New-plan-member lookback period
    2-4 weeksRestasis transition period

    Coverage Criteria Overview

    Restasis and Restasis Multidose — Initial Therapy

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of dry eye disease
    • Trial and failure, or intolerance to an artificial tears product
    • ONE of the following

      • Member will not be using ophthalmic anti-inflammatory drugs concurrently with the requested drug
      • BOTH of the following

        • Member will be using ophthalmic anti-inflammatory drugs concurrently with the requested drug
        • The ophthalmic anti-inflammatory drugs will be used concurrently for a short period while transitioning to monotherapy with the requested drug2 to 4 weeks

    Miebo, Tryptyr, and Xiidra — Initial Therapy

    Covered when ALL of the following criteria are met:

    ALL of the following

    • Diagnosis of dry eye disease
    • Trial and failure, or intolerance to artificial tears products

    Continuation Therapy

    Requests for reauthorization will be approved when ALL of the following criteria are met:

    ALL of the following

    • Member demonstrates a positive response to therapy

    Initial Therapy Criteria

    Restasis and Restasis Multidose

    Restasis and Restasis Multidose initial requests require all of the following criteria, including one of the two concurrent anti-inflammatory pathways.

    All initial therapy criteria

    • Diagnosis of dry eye disease.
    • Artificial tears: Trial and failure of, or intolerance to, an artificial tears product.
    • ONE of the following anti-inflammatory pathways

      • No concurrent use: The member will not be using ophthalmic anti-inflammatory drugs concurrently with the requested drug.

    Continuation and Reauthorization

    All Covered Products

    Reauthorization requests will be approved when the following criterion is met.

    Positive response: The member demonstrates a positive response to therapy.

    Required Treatment Sequence

    StepPrior therapyCoverage requirement
    1Artificial tearsTrial and failure of, or intolerance to, artificial tears is required before initiating the requested product.

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required under the Commercial/Exchange pharmacy benefit for the covered dry eye disease products listed below.

    • Miebo (perfluorohexyloctane ophthalmic solution)
    • Restasis (cyclosporine ophthalmic emulsion)
    • Restasis Multidose
    • Tryptyr (acoltremon ophthalmic solution)
    • Xiidra (lifitegrast ophthalmic solution)
    Step Therapy

    Artificial Tears Prerequisite

    Before coverage of the requested product, document a trial and failure of, or intolerance to, an artificial tears product or products, as applicable.

    • Restasis and Restasis Multidose: trial and failure of, or intolerance to, an artificial tears product

    Dry Eye Disease Background

    Dry eye disease involves signs and symptoms associated with inadequate tear production, tear-film dysfunction, or ocular surface disease. Covered therapies address these conditions through different mechanisms: Miebo is a semifluorinated alkane, Tryptyr is a TRPM8 thermoreceptor agonist, and Xiidra treats the signs and symptoms of dry eye disease. Restasis and Restasis Multidose are calcineurin inhibitor therapies intended to increase tear production when reduced production is presumed to result from ocular inflammation associated with keratoconjunctivitis sicca.

    Policy Definitions

    New member to the plan
    DefinitionA member whose coverage effective date is less than or equal to 90 days.
    Transition to monotherapy
    DefinitionUse of ophthalmic anti-inflammatory therapy concurrently with the requested drug for a short period of 2 to 4 weeks while transitioning to monotherapy with the requested drug.
    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyDry Eye Disease: Miebo, Restasis, Restasis Multidose, Tryptyr, and Xiidra
    Policy CodePolicy N/A
    Change TypeMaterial revision
    Effective DateJan 1, 202743d
    Last ReviewSep 9, 2026
    Next Review DateNot specified
    Key ActionSubmit prior authorization with documentation of dry eye disease and trial and failure of, or intolerance to, artificial tears.
    SourceLink
    On This Page
    Coverage Criteria OverviewInitial Therapy CriteriaContinuation and ReauthorizationRequired Treatment SequenceAuthorization and Documentation RequirementsDry Eye Disease BackgroundPolicy Definitions
    Concurrent use during transition: The member will be using ophthalmic anti-inflammatory drugs concurrently with the requested drug for a short period while transitioning to monotherapy with the requested drug.2 to 4 weeks

    Miebo, Tryptyr, and Xiidra

    Miebo, Tryptyr, and Xiidra initial requests require all of the following criteria.

    All initial therapy criteria

    • Diagnosis of dry eye disease.
    • Artificial tears: Trial and failure of, or intolerance to, artificial tears products.
  1. Miebo, Tryptyr, and Xiidra: trial and failure of, or intolerance to, artificial tears products
  2. Documentation Required

    New-Member Current-Treatment Records

    For members whose coverage effective date is 90 days or less, submit medical records documenting that the member is currently receiving treatment with the requested drug. This requirement does not apply when the product was obtained as samples or through a manufacturer's patient assistance program.

    • Confirm the member's coverage effective date is 90 days or less.
    • Submit current-treatment records for the requested drug.
    • Exclude treatment obtained as samples or through a manufacturer's patient assistance program.
    Documentation Required

    Clinical Criteria Documentation

    Document the diagnosis and prerequisite treatment history for the requested product. For Restasis or Restasis Multidose, also document the applicable concurrent ophthalmic anti-inflammatory drug plan.

    • Diagnosis of dry eye disease
    • Trial and failure of, or intolerance to, artificial tears
    • For Restasis or Restasis Multidose: the member will not use ophthalmic anti-inflammatory drugs concurrently; or, if concurrent use is planned, the drugs will be used for a short period of 2 to 4 weeks while transitioning to monotherapy with the requested drug
    Documentation Required

    Continuation Requires Positive Response

    For reauthorization, submit documentation that the member demonstrates a positive response to therapy.

    • Positive response to the requested therapy is required for continuation of treatment.
    Denial Risk

    Failure to Meet Clinical Criteria

    Coverage may be denied when the required diagnosis or prerequisite treatment criteria are not met.

    • No documented diagnosis of dry eye disease
    • No documented trial and failure of, or intolerance to, artificial tears
    • For Restasis or Restasis Multidose, failure to meet the applicable concurrent ophthalmic anti-inflammatory drug criteria